IGF-1 LR3 vs Metformin
limited vs FDA Approved
monitor Researched · 90% May mitigate insulin resistance.
Molecular Data
IGF-1 LR3 Metformin
Weight — 129.16 Da
Half-life 20-30 hours ~5 hours
Chain 83 amino acids —
Type Synthetic IGF-1 analog Biguanide (C4H11N5)
Key Benefits
IGF-1 LR3
01 Approximately 3x more potent than native IGF-1
02 Promotes muscle hypertrophy and hyperplasia in animal models
03 15-20% lean mass gains observed in 4-week rat studies
04 Anti-catabolic effects preserve muscle during cachexia
05 20-30 hour half-life for sustained effects
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
IGF-1 LR3
20-100 mcg daily (start low at 20-30 mcg) / Once daily, or split AM/PM for higher doses
Beginner Protocol 20-30mcg Once daily post-workout
Intermediate 40-60mcg Once daily
Advanced 80-100mcg Once or split AM/PM
Women's Protocol 10-20mcg Once daily
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
IGF-1 LR3
Hypoglycemia (lasting up to 30 hours) - CRITICAL
Water retention
Joint stiffness
Muscle soreness
Increased pump during workouts
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
NEVER approved for human use - research chemical only
Cancer history or undiagnosed growths
May cause organ hypertrophy (heart, intestines)
WADA prohibited - causes failed drug tests
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
IGF-1 LR3 Metformin
Status limited FDA Approved
References 4 studies 5 studies
Latest November 2024 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.